Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians

Lindsay Renee Grant, Laura L Hammitt, Sarah E. O’Brien, Michael R. Jacobs, Connie Donaldson, Robert C Weatherholtz, Raymond Reid, Mathuram Santosham, Katherine L O'Brien

Research output: Contribution to journalArticle

Abstract

BACKGROUND:: Community-wide impact of pneumococcal conjugate vaccines (PCV) is conferred by reductions in vaccine-type nasopharyngeal carriage. We evaluated the impact of PCV13on carriage of PCV13-specific types (1, 3, 5, 6A, 7F, 19A) and 6C among American Indians. METHODS:: A nasopharyngeal specimen was collected from community members of all ages between January 2010 and April 2012 (3 months before and 24 months after PCV13 introduction). Pneumococci were isolated by culture and serotyped using antisera. Monthly carriage prevalence and PCV13 coverage was calculated to identify the timing of vaccine impact relative to PCV13 introduction. Prevalence ratios (PR) were used to compare PCV13-specific carriage before and in Years 1 and 2 of PCV13 use. Coverage was calculated according to age and number of doses received. RESULTS:: 6645 participants (2859

Original languageEnglish (US)
JournalPediatric Infectious Disease Journal
DOIs
StateAccepted/In press - May 11 2016

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians'. Together they form a unique fingerprint.

  • Cite this